Literature DB >> 7480761

Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization.

C Bartolozzi1, R Lencioni, D Caramella, C Vignali, R Cioni, S Mazzeo, M Carrai, G Maltinti, A Capria, P F Conte.   

Abstract

PURPOSE: To compare the efficacy of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection (PEI) versus repeated TACE in the treatment of large hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Fifty-three patients with cirrhosis and a large HCC (main tumor, 3.1-8.0 cm in diameter with no more than two daughter nodules) were enrolled in a prospective, randomized study. Twenty-six patients underwent a single TACE session followed by PEI (TACE-PEI group), whereas 27 patients underwent two to five TACE sessions (TACE group). Both groups of patients were similar with regard to liver function. Follow-up ranged from 8 to 39 months.
RESULTS: Complete therapeutic responses were higher (P < .05) and tumor recurrences during follow-up were lower (P < .05) in the TACE-PEI group than in the TACE group. Patients in the TACE-PEI group survived longer than those in the TACE group, although the difference was not significant (P > .1). The rates of survival without recurrence were better in the TACE-PEI group than in the TACE group (P < .05).
CONCLUSION: Use of a single TACE session combined with PEI is more effective than repeated TACE in the treatment of large HCC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7480761     DOI: 10.1148/radiology.197.3.7480761

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  44 in total

1.  Combined transarterial chemoembolization and arterial administration of Bletilla striata in treatment of liver tumor in rats.

Authors:  Jun Qian; Daryusch Vossoughi; Dirk Woitaschek; Elsie Oppermann; Wolf O Bechstein; Wei-Yong Li; Gan-Sheng Feng; Thomas Vogl
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

2.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 3.  Treatment of hepatocarcinoma.

Authors:  Beatrice Gerard; Harry Bleiberg
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

4.  Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis.

Authors:  Feng Xie; Jiajie Zang; Xiaojing Guo; Feng Xu; Rongxi Shen; Long Yan; Jiamei Yang; Jia He
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-18       Impact factor: 4.553

5.  TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis.

Authors:  Na Wang; Quanlin Guan; Kai Wang; Bingdong Zhu; Wenzhen Yuan; Peng Zhao; Xiaowei Wang; Yongxun Zhao
Journal:  Med Oncol       Date:  2010-07-15       Impact factor: 3.064

6.  Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation?

Authors:  Jung Hyeok Kwon
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

Review 7.  Ethanol injection for the treatment of hepatic tumours.

Authors:  C Bartolozzi; R Lencioni
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

8.  Future perspectives for hepatocellular carcinoma.

Authors:  W Y Lau
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

Review 9.  Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis.

Authors:  Lili Gu; Huiling Liu; Linlin Fan; Yuanjun Lv; Zhuang Cui; Yan Luo; Yuanyuan Liu; Guang Li; Changping Li; Jun Ma
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

Review 10.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.